about
A specific clinical pattern of camptocormia in Parkinson's diseaseThe value of magnetic resonance imaging as a biomarker for amyotrophic lateral sclerosis: a systematic review1H-NMR-based metabolomic profiling of CSF in early amyotrophic lateral sclerosisAre Upper-Body Axial Symptoms a Feature of Early Parkinson's Disease?Efficient and automated large-scale detection of structural relationships in proteins with a flexible alignerMemantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study.[Thulium laser evoked potentials. Normative values for the arms and legs]Ceruloplasmin activity and iron chelation treatment of patients with Parkinson's disease.[Systemic lupus erythematosus presenting with recurrent psychiatric disturbances]Choreic movements induced by cibenzoline: an Ic class antiarrhythmic effect?Targeting chelatable iron as a therapeutic modality in Parkinson's disease.Post translational changes to α-synuclein control iron and dopamine trafficking; a concept for neuron vulnerability in Parkinson's disease.Iron metabolism disturbance in a French cohort of ALS patientsMethylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial.Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease.External globus pallidus stimulation modulates brain connectivity in Huntington's disease.Relationship between oscillations in the basal ganglia and synchronization of cortical activity.Magnetic Resonance Imaging Features of the Nigrostriatal System: Biomarkers of Parkinson's Disease Stages?Paradoxical response of VEGF expression to hypoxia in CSF of patients with ALS.The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson's disease.Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's diseaseVentilatory Dysfunction in Parkinson's DiseasePhenotypic variability in ARCA2 and identification of a core ataxic phenotype with slow progression.Dopaminergic and non-dopaminergic pharmacological hypotheses for gait disorders in Parkinson's disease.New pharmacological options for treating advanced Parkinson's disease.Clinical syndromes: Parkinsonian gait.Regional siderosis: a new challenge for iron chelation therapy.Platelet microparticles: detection and assessment of their paradoxical functional roles in disease and regenerative medicine.Clinical implications of neuropharmacogenetics.Disruption of TCA Cycle and Glutamate Metabolism Identified by Metabolomics in an In Vitro Model of Amyotrophic Lateral Sclerosis.Bioavailable Trace Metals in Neurological Diseases.Clinical quantitative susceptibility mapping (QSM): Biometal imaging and its emerging roles in patient care.Untargeted 1H-NMR metabolomics in CSF: toward a diagnostic biomarker for motor neuron disease.Clinical features of amyotrophic lateral sclerosis and their prognostic value.Ethical considerations and palliative care in patients with amyotrophic lateral sclerosis: A review.RNA-binding disturbances as a continuum from spinocerebellar ataxia type 2 to Parkinson disease.Composite cerebellar functional severity score: validation of a quantitative score of cerebellar impairment.Tailor-made purified human platelet lysate concentrated in neurotrophins for treatment of Parkinson's disease.[West Nile meningoencephalitis in an immunocompromised patient].[Acute rhombencephalitis with fever and bilateral hearing loss secondary to Gougerot-Sjögren's syndrome]
P50
Q24678586-C2FE1BF6-FD48-4C77-BD2E-536E62986D13Q28067928-046F632B-3A2F-4F7D-8545-8E58159D4CABQ28475721-1CE74C81-3A49-46BE-AFC9-11A51A86837BQ30372617-83CA3659-F2CD-4778-A573-3DE969617903Q30383167-F815E4B6-B309-4955-9BCE-145219D51ABFQ30538692-2743F043-DC23-49B9-BAA0-FA6F568FA401Q30638546-F9BDD5AD-6A2D-4AA4-BC03-1C4CE27F3532Q30944822-3595ADA8-E502-4432-80D9-7548B8CCFDB2Q30966801-F2D110D6-01E4-4C5C-B4D6-84F3CBEABB11Q31441576-87F12A42-6C23-48BB-9E72-D54C43F19635Q33768106-61A13B08-C1D6-4386-BEAD-A32708CD7A5DQ33776138-DDF2089E-3AB8-4A15-A386-2CD85E010CB7Q33914518-16C4E36A-AF30-4098-8819-E8EB399A2F86Q34278569-DD16F481-E4A7-492A-B53E-FB656B57FE54Q34604998-5894ED71-2FC0-46DF-B1AE-078BC506E959Q34627479-1F7A5690-3E51-4D8A-A3B0-511F2EE77E8FQ35032132-37554C34-9BE8-4359-A819-44247CCA164FQ35976522-C13AB34C-318B-4DBA-8250-23A27547B4FDQ36142587-B24A0262-9AEC-44B0-A208-B07713F2D314Q36226345-B9142829-6C7B-4AF9-B5A4-E280A41DF1E1Q36227392-15377D1E-380B-48C8-A279-64CFD4312FE4Q37225132-07E17DCF-9CFA-498A-8DEB-43FCF0A043B9Q37350136-5E0C0B6F-2B99-4E5D-A3B1-A8819909D46DQ37693988-7D6EB6B2-6ACE-4210-AA37-61DFB4B5AA5FQ38134950-2614A4B8-5B5C-4513-9D63-79015AC867DFQ38153328-DDCDE904-FD6E-4866-B734-D93543CFBF17Q38178660-9A774E41-0344-4A80-B2EE-93F4FBE89AF9Q38211678-4C726648-4632-4667-8372-9314A60DDBC9Q38501891-48B34B5D-A5FD-4193-AFBB-D345E01E6AE1Q38811833-62896E74-1CCA-48BA-A14A-36D45DF952D7Q38967236-E7CC858A-B97D-4D14-A1D0-ECF8AB88EA95Q39179797-ADB67DD5-D415-4F47-81BE-EC6AA7EFC808Q39241061-069D6329-3F7F-4508-998A-FA5F61438484Q39287934-C727D556-2ABA-4E95-AA3F-4E27241CBFE3Q39288964-AE96C05D-5006-4F5D-B751-574CA545C6F5Q39356825-D198FA13-14A3-4F1F-82B2-007612F04D63Q40108210-56DEB559-35C7-459C-9C70-793EFCF282DEQ40114833-D76A73E0-5245-4A00-A346-3F0F8643403AQ40403778-C3D6B82E-0A0F-4CD1-98CD-EAD0EF76505BQ40584076-01A3D488-834E-4DBF-BE08-7DBF2428B3A9
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
David Devos
@ast
David Devos
@de
David Devos
@en
David Devos
@es
David Devos
@fr
David Devos
@nl
David Devos
@sl
type
label
David Devos
@ast
David Devos
@de
David Devos
@en
David Devos
@es
David Devos
@fr
David Devos
@nl
David Devos
@sl
altLabel
D Devos
@en
prefLabel
David Devos
@ast
David Devos
@de
David Devos
@en
David Devos
@es
David Devos
@fr
David Devos
@nl
David Devos
@sl
P214
P1053
E-4059-2013
P106
P1153
7004062843
P21
P213
0000 0003 5945 9484
P214
P2798
P31
P3829
P4012
P496
0000-0002-2417-799X
P735
P7859
viaf-220211546